ZIOPHARM肿瘤

ZIOP NASDAQ
5.72
+0.50
+9.58%
盘后: 5.75 +0.03 +0.52% 17:00 06/17 EDT
开盘
5.29
昨收
5.22
最高
5.83
最低
5.19
成交量
628.68万
成交均量(3M)
171.06万
52周最高
5.72
52周最低
1.560
换手率
3.87%
市值
9.29亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供ZIOPHARM肿瘤 ZIOP股票价格,ZIOPHARM肿瘤股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
展开 >

最近浏览

名称
价格
涨跌幅